Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinomaYuki Nemoto, Toshio Takagi, Hiroki Ishihara et al.|International Urology and Nephrology|2021Cited by 18
Therapeutic role of deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumabMaki Yoshino, Toshio Takagi, Hiroki Ishihara et al.|Japanese Journal of Clinical Oncology|2022Cited by 16
Association of tumor burden with outcome in first-line therapy with nivolumab plus ipilimumab for previously untreated metastatic renal cell carcinomaHiroki Ishihara, Toshio Takagi, Tsunenori Kondo et al.|Japanese Journal of Clinical Oncology|2021Cited by 15
Changes in Real-World Outcomes in Patients with Metastatic Renal Cell Carcinoma from the Molecular-Targeted Therapy Era to the Immune Checkpoint Inhibitor EraHiroki Ishihara, Toshio Takagi, Yuki Nemoto et al.|Targeted Oncology|2022Cited by 10
Impact of Body Mass Index on Outcomes in an Asian population of Advanced Renal Cell Carcinoma and Urothelial Carcinoma Treated With Immune Checkpoint InhibitorsHiroki Ishihara, Toshio Takagi, Yudai Ishiyama et al.|Clinical Genitourinary Cancer|2022Cited by 6